Glenzocimab is a humanized monoclonal antibody fragment (fab) directed against the human platelet glycoprotein GPVI, and a novel antithrombotic drug developed by Acticor-Biotech.
Glenzocimab is being developed for use during the acute phase of ischemic stroke as an add-on therapy to thrombolysis, with or without mechanical thrombectomy.
Since 2020, the action of glenzocimab has also been explored regarding the treatment of Acute Respiratory Distress Syndrome (ARDS) in patients infected with SARS-Cov-2.